- Home
- AEVA vs OCS Comparison
AEVA vs OCS Comparison
Compare AEVA & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- OCS
- Stock Information
- Founded
- AEVA 2019
- OCS 2003
- Country
- AEVA United States
- OCS Switzerland
- Employees
- AEVA N/A
- OCS N/A
- Industry
- AEVA Auto Parts:O.E.M.
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- OCS Health Care
- Exchange
- AEVA Nasdaq
- OCS Nasdaq
- Market Cap
- AEVA 1.0B
- OCS 1.0B
- IPO Year
- AEVA N/A
- OCS N/A
- Fundamental
- Price
- AEVA $25.13
- OCS $19.28
- Analyst Decision
- AEVA Buy
- OCS Strong Buy
- Analyst Count
- AEVA 6
- OCS 3
- Target Price
- AEVA $16.20
- OCS $35.33
- AVG Volume (30 Days)
- AEVA 2.1M
- OCS 31.4K
- Earning Date
- AEVA 08-06-2025
- OCS 05-08-2025
- Dividend Yield
- AEVA N/A
- OCS N/A
- EPS Growth
- AEVA N/A
- OCS N/A
- EPS
- AEVA N/A
- OCS N/A
- Revenue
- AEVA $10,326,000.00
- OCS $847,333.00
- Revenue This Year
- AEVA $94.59
- OCS $18.70
- Revenue Next Year
- AEVA $165.22
- OCS $1,059.78
- P/E Ratio
- AEVA N/A
- OCS N/A
- Revenue Growth
- AEVA 95.90
- OCS N/A
- 52 Week Low
- AEVA $2.20
- OCS $10.79
- 52 Week High
- AEVA $28.10
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- AEVA 68.28
- OCS 51.81
- Support Level
- AEVA $21.90
- OCS $18.64
- Resistance Level
- AEVA $28.10
- OCS $19.73
- Average True Range (ATR)
- AEVA 2.07
- OCS 0.58
- MACD
- AEVA 0.25
- OCS -0.07
- Stochastic Oscillator
- AEVA 74.17
- OCS 36.57
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.